Critical Review: Fennec Pharmaceuticals (FENC) vs. The Competition
Fennec Pharmaceuticals (NASDAQ: FENC) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Fennec Pharmaceuticals to similar companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.
Earnings & Valuation
This table compares Fennec Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Fennec Pharmaceuticals||N/A||-$2.78 million||-23.35|
|Fennec Pharmaceuticals Competitors||$276.62 million||-$22.88 million||89.31|
Volatility and Risk
Fennec Pharmaceuticals has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals’ competitors have a beta of 2.14, indicating that their average share price is 114% more volatile than the S&P 500.
Insider and Institutional Ownership
38.2% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.7% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Fennec Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fennec Pharmaceuticals Competitors||1283||3697||12290||266||2.66|
Fennec Pharmaceuticals presently has a consensus price target of $19.00, indicating a potential upside of 103.43%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.21%. Given Fennec Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Fennec Pharmaceuticals is more favorable than its competitors.
This table compares Fennec Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fennec Pharmaceuticals Competitors||-5,744.26%||-102.44%||-37.34%|
Fennec Pharmaceuticals competitors beat Fennec Pharmaceuticals on 7 of the 13 factors compared.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.